Multiple myeloma in older adults: an update

Madappa N. Kundranda, Joseph R Mikhael

Research output: Contribution to journalArticle

Abstract

Multiple myeloma (MM) is an uncommon malignant plasma cell disorder that often presents in older adults. An accurate diagnosis is critical as a spectrum of plasma cell disorders have been defined, including monoclonal gammopathy of undetermined significance, smouldering/asymptomatic multiple myeloma, multiple myeloma, and plasma cell leukemia. Although multiple myeloma is incurable disease, survival over 7 years is possible, during which patients can enjoy a good quality of life. Many therapeutic options now exist for individuals with MM who are ineligible for autologous stem cell transplantation; these include adding thalidomide, bortezomib, and lenalidomide to the current standard ofmelphalan and prednisone.

Original languageEnglish (US)
Pages (from-to)382-388
Number of pages7
JournalGeriatrics and Aging
Volume12
Issue number8
StatePublished - Sep 2009

Fingerprint

Multiple Myeloma
Plasma Cells
Plasma Cell Leukemia
Monoclonal Gammopathy of Undetermined Significance
Thalidomide
Stem Cell Transplantation
Prednisone
Quality of Life
Survival

Keywords

  • MGUS
  • Multiple myeloma
  • Older adults
  • Plasma cell leukemia
  • Supportive care

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Aging
  • Gerontology

Cite this

Kundranda, M. N., & Mikhael, J. R. (2009). Multiple myeloma in older adults: an update. Geriatrics and Aging, 12(8), 382-388.

Multiple myeloma in older adults : an update. / Kundranda, Madappa N.; Mikhael, Joseph R.

In: Geriatrics and Aging, Vol. 12, No. 8, 09.2009, p. 382-388.

Research output: Contribution to journalArticle

Kundranda, MN & Mikhael, JR 2009, 'Multiple myeloma in older adults: an update', Geriatrics and Aging, vol. 12, no. 8, pp. 382-388.
Kundranda MN, Mikhael JR. Multiple myeloma in older adults: an update. Geriatrics and Aging. 2009 Sep;12(8):382-388.
Kundranda, Madappa N. ; Mikhael, Joseph R. / Multiple myeloma in older adults : an update. In: Geriatrics and Aging. 2009 ; Vol. 12, No. 8. pp. 382-388.
@article{9f630be431cd46338652d94ce2f88f3b,
title = "Multiple myeloma in older adults: an update",
abstract = "Multiple myeloma (MM) is an uncommon malignant plasma cell disorder that often presents in older adults. An accurate diagnosis is critical as a spectrum of plasma cell disorders have been defined, including monoclonal gammopathy of undetermined significance, smouldering/asymptomatic multiple myeloma, multiple myeloma, and plasma cell leukemia. Although multiple myeloma is incurable disease, survival over 7 years is possible, during which patients can enjoy a good quality of life. Many therapeutic options now exist for individuals with MM who are ineligible for autologous stem cell transplantation; these include adding thalidomide, bortezomib, and lenalidomide to the current standard ofmelphalan and prednisone.",
keywords = "MGUS, Multiple myeloma, Older adults, Plasma cell leukemia, Supportive care",
author = "Kundranda, {Madappa N.} and Mikhael, {Joseph R}",
year = "2009",
month = "9",
language = "English (US)",
volume = "12",
pages = "382--388",
journal = "Geriatrics and Aging",
issn = "1488-8408",
publisher = "Geriatrics and Aging",
number = "8",

}

TY - JOUR

T1 - Multiple myeloma in older adults

T2 - an update

AU - Kundranda, Madappa N.

AU - Mikhael, Joseph R

PY - 2009/9

Y1 - 2009/9

N2 - Multiple myeloma (MM) is an uncommon malignant plasma cell disorder that often presents in older adults. An accurate diagnosis is critical as a spectrum of plasma cell disorders have been defined, including monoclonal gammopathy of undetermined significance, smouldering/asymptomatic multiple myeloma, multiple myeloma, and plasma cell leukemia. Although multiple myeloma is incurable disease, survival over 7 years is possible, during which patients can enjoy a good quality of life. Many therapeutic options now exist for individuals with MM who are ineligible for autologous stem cell transplantation; these include adding thalidomide, bortezomib, and lenalidomide to the current standard ofmelphalan and prednisone.

AB - Multiple myeloma (MM) is an uncommon malignant plasma cell disorder that often presents in older adults. An accurate diagnosis is critical as a spectrum of plasma cell disorders have been defined, including monoclonal gammopathy of undetermined significance, smouldering/asymptomatic multiple myeloma, multiple myeloma, and plasma cell leukemia. Although multiple myeloma is incurable disease, survival over 7 years is possible, during which patients can enjoy a good quality of life. Many therapeutic options now exist for individuals with MM who are ineligible for autologous stem cell transplantation; these include adding thalidomide, bortezomib, and lenalidomide to the current standard ofmelphalan and prednisone.

KW - MGUS

KW - Multiple myeloma

KW - Older adults

KW - Plasma cell leukemia

KW - Supportive care

UR - http://www.scopus.com/inward/record.url?scp=70449553303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449553303&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:70449553303

VL - 12

SP - 382

EP - 388

JO - Geriatrics and Aging

JF - Geriatrics and Aging

SN - 1488-8408

IS - 8

ER -